Eurofins Scientific SE Stock OTC Markets
Stocks
ERFSF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
OTC Markets
22:45:37 05/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 87.18 USD | +1.43% |
|
-3.01% | +18.94% |
| 10-02 | Eurofins Completes Sale of MET Labs Business | MT |
| 10-01 | UL Solutions Completes Acquisition of Eurofins' Electrical, Electronics Business | MT |
| Market Cap | 13.11B 14.7B 12.22B 11.12B 20.94B 1,416B 21.09B 148B 57.44B 723B 55.18B 53.99B 2,323B | P/E 2026 * |
25.2x | P/E 2027 * | 19.9x |
|---|---|---|---|---|---|
| Enterprise Value | 16.48B 18.47B 15.35B 13.97B 26.31B 1,779B 26.51B 186B 72.18B 908B 69.35B 67.85B 2,919B | EV / Sales 2026 * |
2.19x | EV / Sales 2027 * | 2.03x |
| Free-Float |
60.39% | Yield 2026 * |
1.06% | Yield 2027 * | 1.2% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
London S.E.
| 0MV5 | Delayed | |
|
OTC Markets
| ERFSF | Delayed | |
|
Xetra
| ESF0 | Delayed | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
Tradegate
| ESF0 | Real-time | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript: Eurofins Scientific SE
| 1 day | +1.43% | ||
| 1 week | -3.01% | ||
| Current month | +2.80% | ||
| 1 month | +1.45% | ||
| 3 months | +12.43% | ||
| 6 months | +11.46% | ||
| Current year | +18.94% |
| 1 week | 81.96 |  | 87.79 |
| 1 month | 79.74 | | 92.97 |
| Current year | 64.95 | | 92.97 |
| 1 year | 64.95 | | 92.97 |
| 3 years | 44.61 | | 92.97 |
| 5 years | 44.61 | | 131.04 |
| 10 years | 44.61 | | 879.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 01/01/1987 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/01/2015 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 01/01/1987 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 01/01/2015 |
Valérie Hanote
BRD | Director/Board Member | 60 | 01/01/1990 |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.54B 8.45B 7.02B 6.39B 12.03B 814B 12.12B 84.84B 33.01B 415B 31.71B 31.03B 1,335B | 7.94B 8.91B 7.4B 6.74B 12.68B 858B 12.78B 89.43B 34.79B 438B 33.43B 32.71B 1,407B |
| Net income | 531M 595M 495M 450M 848M 57.31B 854M 5.98B 2.33B 29.25B 2.23B 2.19B 94.03B | 660M 739M 615M 559M 1.05B 71.22B 1.06B 7.43B 2.89B 36.35B 2.78B 2.72B 117B |
| Net Debt | 3.37B 3.77B 3.14B 2.85B 5.37B 363B 5.41B 37.89B 14.74B 185B 14.16B 13.86B 596B | 3.03B 3.4B 2.83B 2.57B 4.84B 328B 4.88B 34.15B 13.29B 167B 12.77B 12.49B 537B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/10/26 | $87.18 | +1.43% | 1,846 |
| 02/10/26 | $85.95 | +4.16% | 954 |
| 01/10/26 | $82.52 | -2.70% | 1,695 |
| 30/09/26 | $84.81 | -3.30% | 2,085 |
| 29/09/26 | $87.70 | -3.96% | 1,863 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
- ERFSF Stock
Select your edition
All financial news and data tailored to specific country editions
